Abstract 1213P
Background
HRR gene alterations, which are enriched in prostate cancer (PC), are associated with sensitivity to PARP inhibitors. However, the tests available to detect HRR gene alterations are limited and usually large NGS panels with high cost and long turnaround time (TAT). A novel HANDLE (Halo-shape ANnealing and Defer-Ligation Enrichment) based NGS assay, AmoyDx HRD Complete was established to evaluate single nucleotide variant (SNV), short insertion and deletion (InDel) and homozygous deletion (HD) of 17 HRR genes in PC tissues, with 4 days TAT.
Methods
Sensitivity was validated in serially diluted cell lines with varying DNA input: with gradient mutation allele frequency (MAF) (7%, 5%, 3%) for SNV/InDel; with different tumor content (50%, 40%, 30%, 20%) for HD. Specificity was validated in wild type cell lines. Testing success rate was evaluated using 100 formalin-fixed paraffin-embedded (FFPE) PC tissues (up to 10 years old). A “three-tube” library process was developed for samples which failed DNA, library, or sequencing QC with standard process. Accuracy was assessed in >200 FFPE PC tissues, using commercially available AmoyDx HRD54 NGS kit (hybridization capture based) and AmoyDx BRCA1/2 NGS kit (CE-IVD) as reference tests.
Results
Sensitivity of HRR SNV/InDel was 99.4% (179/180, MAF 5%) with 30ng DNA. Sensitivity of HRR HD was 100% at gene level with 30% tumor content and at exon level with 40% tumor content with 100ng DNA. Specificity was 100%. 54/100 (54%) PC tissues had valid sequencing results using standard process, whereas the “three-tube” library improved the success rate to 84%. For HRR SNV/InDel accuracy, 98/100 PC tissues showed concordant results with HRD54 kit (PPA 96.8%, NPA 98.6%, OPA 98.0%). For HRR HD accuracy, 130/132 PC tissues showed concordant results with HRD54 kit (PPA 100%, NPA 98.4%, OPA 98.5%). Accuracy of BRCA1/2 SNV/InDel was further verified with 100% concordance with BRCA1/2 kit.
Conclusions
With high sensitivity and specificity, short TAT and high success rate, the CE marked (CE-IVD) HRD Complete assay provides a robust and reliable test approach to PC patients that may guide them for a better treatment option.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Janssen.
Disclosure
X. Ye, U. Singh, K. Bell, K. Urtishak, L. Luo, X. Lyu, M. Gormley, D.A. Smirnov, L. Zhou: Financial Interests, Institutional, Full or part-time Employment: Johnson and Johnson. P. Cheng, Y. Guo, J. Wang, W. Xu, Z. Huang, X. Chen, S. Liu, S. Yang, W. Shi, C. Zhu: Financial Interests, Personal, Full or part-time Employment: Amoy Diagnostics.
Resources from the same session
1794P - Prognostic role of metastatic site in patients with de novo metastatic prostate cancer: A population-based analysis in new hormonal agents era
Presenter: Emre Yekeduz
Session: Poster session 14
1795P - China ARCHES: A multicenter phase III randomized double-blind placebo (PBO)-controlled efficacy and safety trial of enzalutamide (ENZA) + androgen deprivation therapy (ADT) vs PBO + ADT in Chinese patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC)
Presenter: Gongqian Zeng
Session: Poster session 14
1796P - Real-world analysis of metastatic hormone-sensitive prostate cancer: Are randomized clinical trials more trustworthy? Insights from PIONEER, the European network of excellence for big data in prostate cancer
Presenter: Juan Gómez Rivas
Session: Poster session 14
1797P - Application of novel machine learning model in [68Ga] Ga-PSMA-11 PET/CT: Predicting survival in oligometastatic prostate cancer patients
Presenter: Mikaela Dell'Oro
Session: Poster session 14
1800P - Differential tumor gene-expression profiling of patients (pts) with de-novo metastatic castration-sensitive prostate cancer (dn-mCSPC) versus (vs.) mCSPC relapsing after prior localized therapy (PLT-mCSPC)
Presenter: Vinay Mathew Thomas
Session: Poster session 14
1803P - Phase I/II study of bavdegalutamide, a PROTAC androgen receptor (AR) degrader in metastatic castration-resistant prostate cancer (mCRPC): Radiographic progression-free survival (rPFS) in patients (pts) with <italic>AR</italic> ligand-binding domain (LBD) mutations
Presenter: Daniel Petrylak
Session: Poster session 14